Cargando…
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
We recently discovered a superantigen-like motif, similar to Staphylococcal enterotoxin B (SEB), near the S1/S2 cleavage site of SARS-CoV-2 Spike protein, which might explain the multisystem-inflammatory syndrome (MIS-C) observed in children and cytokine storm in severe COVID-19 patients. We show he...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/ https://www.ncbi.nlm.nih.gov/pubmed/33269352 http://dx.doi.org/10.1101/2020.11.24.395079 |
_version_ | 1783617696511819776 |
---|---|
author | Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet |
author_facet | Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet |
author_sort | Cheng, Mary Hongying |
collection | PubMed |
description | We recently discovered a superantigen-like motif, similar to Staphylococcal enterotoxin B (SEB), near the S1/S2 cleavage site of SARS-CoV-2 Spike protein, which might explain the multisystem-inflammatory syndrome (MIS-C) observed in children and cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif, and in particular its PRRA insert, to inhibit infection by blocking the access of host cell proteases, TMPRSS2 or furin, to the cleavage site. The high affinity of 6D3 for the furin-cleavage site originates from a poly-acidic segment at its heavy chain CDR2, a feature shared with SARS-CoV-2-neutralizing mAb 4A8. The affinity of 6D3 and 4A8 for this site points to their potential utility as therapeutics for treating COVID-19, MIS-C, or common cold caused by human coronaviruses (HCoVs) that possess a furin-like cleavage site. |
format | Online Article Text |
id | pubmed-7709177 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-77091772020-12-03 A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet bioRxiv Article We recently discovered a superantigen-like motif, similar to Staphylococcal enterotoxin B (SEB), near the S1/S2 cleavage site of SARS-CoV-2 Spike protein, which might explain the multisystem-inflammatory syndrome (MIS-C) observed in children and cytokine storm in severe COVID-19 patients. We show here that an anti-SEB monoclonal antibody (mAb), 6D3, can bind this viral motif, and in particular its PRRA insert, to inhibit infection by blocking the access of host cell proteases, TMPRSS2 or furin, to the cleavage site. The high affinity of 6D3 for the furin-cleavage site originates from a poly-acidic segment at its heavy chain CDR2, a feature shared with SARS-CoV-2-neutralizing mAb 4A8. The affinity of 6D3 and 4A8 for this site points to their potential utility as therapeutics for treating COVID-19, MIS-C, or common cold caused by human coronaviruses (HCoVs) that possess a furin-like cleavage site. Cold Spring Harbor Laboratory 2020-11-24 /pmc/articles/PMC7709177/ /pubmed/33269352 http://dx.doi.org/10.1101/2020.11.24.395079 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator. |
spellingShingle | Article Cheng, Mary Hongying Porritt, Rebecca A. Rivas, Magali Noval Krieger, James M Ozdemir, Asli Beyza Garcia, Gustavo Arumugaswami, Vaithilingaraja Fries, Bettina C. Arditi, Moshe Bahar, Ivet A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_full | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_fullStr | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_full_unstemmed | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_short | A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro |
title_sort | monoclonal antibody against staphylococcal enterotoxin b superantigen inhibits sars-cov-2 entry in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/ https://www.ncbi.nlm.nih.gov/pubmed/33269352 http://dx.doi.org/10.1101/2020.11.24.395079 |
work_keys_str_mv | AT chengmaryhongying amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT porrittrebeccaa amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT rivasmagalinoval amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT kriegerjamesm amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT ozdemiraslibeyza amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT garciagustavo amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arumugaswamivaithilingaraja amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT friesbettinac amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arditimoshe amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT baharivet amonoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT chengmaryhongying monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT porrittrebeccaa monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT rivasmagalinoval monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT kriegerjamesm monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT ozdemiraslibeyza monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT garciagustavo monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arumugaswamivaithilingaraja monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT friesbettinac monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT arditimoshe monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro AT baharivet monoclonalantibodyagainststaphylococcalenterotoxinbsuperantigeninhibitssarscov2entryinvitro |